FDA chief backs 2 new path­ways to spur drug im­por­ta­tion — but an­a­lysts shrug it all off

6 years ago
People
Pharma

Mer­ck­'s Keytru­da makes the cut as a sec­ond-line monother­a­py for cer­tain esophageal can­cer pa­tients

6 years ago
Pharma

Gilead chief Daniel O’Day isn’t done mak­ing head­lines — with more R&D deals and lots of new hires to come

6 years ago
People
Deals

Amarin boost­ed as an­oth­er mile­stone to the FDA’s big Vas­cepa de­ci­sion flies by with no sign of an Ad­Com

6 years ago
R&D

No­var­tis' $18.5B in M&A un­der Vas Narasimhan says a lot about their care­ful — but op­por­tunis­tic — deal strat­e­gy

6 years ago
Deals

Ped­al to the met­al, Am­gen fi­nal­ly has a hot new drug star on its hands — and they have some news

6 years ago
R&D

Bay­er, Ori­on win speedy ap­proval for prostate can­cer drug daro­lu­tamide

6 years ago
Pharma

Welling­ton Part­ners tanks up with $237M for its next life sci fund — same strat­e­gy, but with more cash on hand

6 years ago
Financing

Ap­proval in sight, Per­cep­tive, Or­biMed dou­ble down on Foamix's an­tibi­ot­ic foam to the tune of $64M

6 years ago
Financing

Gates backs de­vel­op­ment work on a long-act­ing con­tra­cep­tive pill

6 years ago
R&D

Found­ing NewLink CEO Charles Link is out; Chi-Med lines up two more drug fil­ings

6 years ago
News Briefing

Eli Lil­ly ax­es an ear­ly-stage PD-L1/TIM-3 bis­pe­cif­ic pro­gram in lat­est pipeline cleanup

6 years ago
R&D

The patent play: Bio­gen gets a PhI­II boost for its bit-bet­ter take on the block­buster MS fran­chise drug Tec­fidera

6 years ago
R&D

Do you want to see what win­ning big in the R&D race looks like in the Big Phar­ma league?

6 years ago
Bioregnum
Opinion

FTC in­ves­ti­gates J&J con­tracts re­gard­ing the drug­mak­er's block­buster Rem­i­cade

6 years ago
Pharma
FDA+

Ve­rastem taps board di­rec­tor and Eli Lil­ly vet Bri­an Stug­lik to right the com­mer­cial boat

6 years ago
People

What is Pfiz­er go­ing to buy next? Al­bert Bourla out­lines his M&A strat­e­gy in the post-Up­john era

6 years ago
Deals
Pharma

No­var­tis’ Zol­gens­ma joins grow­ing list of med­i­cines to lose ac­cel­er­at­ed as­sess­ment sta­tus in EU

6 years ago
FDA+

Strapped for cash, Wood­ford's un­rav­el­ing con­tin­ues as list­ed fund con­sid­ers kick­ing him out as man­ag­er

6 years ago
People

Gen­fit's elafi­bra­nor wins or­phan sta­tus for pri­ma­ry bil­iary cholan­gi­tis; Cidara stock soars on pos­i­tive an­ti-fun­gal ...

6 years ago
News Briefing

Af­ter paint­ing a poor safe­ty pro­file, Pfiz­er and Eli Lil­ly are shoot­ing for a new pain drug OK any­way

6 years ago
R&D

As can­cer de­tec­tion com­pa­nies thrive, Ex­act Sci­ences looks to con­sol­i­date by spend­ing $2.8B to ac­quire peer Ge­nom­ic ...

6 years ago
Deals

Well­come Trust joins warn­ing for no-deal Brex­it, calls on Boris John­son to cast R&D vi­sion

6 years ago
People
Discovery

$20B-plus? Mer­ck keeps rack­ing up PhI­II suc­cess­es, scor­ing on triple neg­a­tive breast can­cer chal­lenge as an­a­lysts ...

6 years ago
R&D
First page Previous page 912913914915916917918 Next page Last page
A service from the Financial Times